Phase I/II Clinical Trial of Ontegimod and Gemcitabine/Nab-paclitaxel as Second Line Therapy for Metastatic Pancreatic Ductal Adenocarcinoma: Reprogramming Tumor-associated Myeloid Cells

Investigators at WashU are testing whether CD11b agonism can reprogram the tumor microenvironment to overcome resistance to checkpoint immunotherapy in advanced, unresectable pancreatic adenocarcinoma. The open-label trial evaluates ontegimod combined with gemcitabine and nab-paclitaxel in a dose de-escalation Phase I, followed by Phase II experimental and control arms.